Ocuphire Pharma Return on Tangible Equity 2010-2024 | IRD
Current and historical return on tangible equity values for Ocuphire Pharma (IRD) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Ocuphire Pharma Return On Tangible Equity Historical Data |
Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
2024-06-30 |
$-0.01B |
$0.04B |
-29.95% |
2024-03-31 |
$-0.01B |
$0.05B |
-23.91% |
2023-12-31 |
$-0.01B |
$0.05B |
-22.35% |
2023-09-30 |
$0.03B |
$0.05B |
66.29% |
2023-06-30 |
$0.02B |
$0.04B |
52.55% |
2023-03-31 |
$0.02B |
$0.04B |
63.16% |
2022-12-31 |
$0.02B |
$0.05B |
75.56% |
2022-09-30 |
$-0.02B |
$0.01B |
-139.39% |
2022-06-30 |
$-0.02B |
$0.02B |
-117.33% |
2022-03-31 |
$-0.02B |
$0.02B |
-115.66% |
2021-12-31 |
$-0.06B |
$0.02B |
-294.74% |
2021-09-30 |
$-0.07B |
$0.02B |
-673.17% |
2021-06-30 |
$-0.07B |
$0.02B |
-1015.38% |
2021-03-31 |
$-0.06B |
$0.01B |
-2440.00% |
2020-12-31 |
$-0.03B |
$-0.01B |
-1111.11% |
2020-09-30 |
$-0.01B |
$0.01B |
-142.86% |
2020-06-30 |
$-0.01B |
$0.01B |
-120.00% |
2020-03-31 |
$-0.01B |
$0.01B |
-88.89% |
2019-12-31 |
$-0.01B |
$-0.01B |
-58.82% |
2019-09-30 |
$-0.01B |
$0.01B |
-67.92% |
2019-06-30 |
$-0.01B |
$0.01B |
-102.13% |
2019-03-31 |
$-0.01B |
$0.02B |
-127.27% |
2018-12-31 |
$-0.01B |
$0.01B |
-130.23% |
2018-09-30 |
$-0.02B |
$0.01B |
-122.45% |
2018-06-30 |
$-0.01B |
$0.01B |
-75.86% |
2018-03-31 |
$-0.01B |
$0.02B |
-38.10% |
2017-12-31 |
$-0.03B |
$0.02B |
-212.24% |
2017-09-30 |
$-0.02B |
$0.02B |
-187.76% |
2017-06-30 |
$-0.03B |
$0.02B |
-196.08% |
2017-03-31 |
$-0.03B |
$0.00B |
-219.61% |
2016-12-31 |
$-0.01B |
$0.02B |
-59.70% |
2016-09-30 |
$-0.01B |
$0.02B |
-69.57% |
2016-06-30 |
$-0.01B |
$0.02B |
-74.29% |
2016-03-31 |
$-0.01B |
$0.02B |
-74.67% |
2015-12-31 |
$-0.01B |
$0.02B |
-69.14% |
2015-09-30 |
$-0.01B |
$0.02B |
-58.43% |
2015-06-30 |
$-0.01B |
$0.02B |
-44.00% |
2015-03-31 |
$-0.01B |
$0.02B |
-29.36% |
2014-12-31 |
$-0.02B |
$0.03B |
-66.67% |
2014-09-30 |
$-0.02B |
$0.03B |
-80.00% |
2014-06-30 |
$-0.02B |
$0.03B |
-98.77% |
2014-03-31 |
$-0.02B |
$0.03B |
-161.40% |
2013-12-31 |
$-0.01B |
$0.01B |
-108.11% |
2013-09-30 |
$-0.01B |
$0.01B |
-82.35% |
2013-06-30 |
$-0.01B |
$0.01B |
-110.34% |
2013-03-31 |
$-0.01B |
$0.01B |
-77.42% |
2012-12-31 |
$-0.01B |
$0.01B |
-75.00% |
2012-09-30 |
$-0.01B |
$0.01B |
-72.73% |
2012-06-30 |
$-0.00B |
$0.01B |
-42.11% |
2012-03-31 |
$-0.01B |
$0.01B |
-87.80% |
2011-12-31 |
$-0.01B |
$0.01B |
-89.80% |
2011-09-30 |
$-0.01B |
$0.01B |
-116.67% |
2011-06-30 |
$-0.01B |
$0.01B |
-96.30% |
2011-03-31 |
$-0.01B |
$0.02B |
-73.33% |
2010-12-31 |
$-0.02B |
$0.01B |
-117.65% |
2010-09-30 |
$-0.01B |
$0.02B |
-86.96% |
2010-06-30 |
$-0.01B |
$0.02B |
-125.71% |
2010-03-31 |
$-0.01B |
$0.01B |
-171.43% |
2009-12-31 |
$-0.00B |
$0.01B |
-53.33% |
Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|